VRTX - Biotechs post record gains in November amid improving outlook
2023-12-03 12:00:30 ET
More on SPDR S&P Biotech ETF
- Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble
- Biopharma Bounce-Back: From Policy Pains To Profitable Plains
- Biotechs rally with gene editing stocks among notable gainers
- Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns
- Seeking Alpha’s Quant Rating on SPDR S&P Biotech ETF
For further details see:
Biotechs post record gains in November amid improving outlook